Cinnamaldehyde supplementation prevents fasting induced hyperphagia, lipid accumulation, and inflammation in high fat diet fed mice.
Cinnamaldehyde, a bioactive component of cinnamon, is increasingly gaining interest for its preventive and therapeutic effects against metabolic complications like type 2 diabetes. This study is an attempt to understand the effect of cinnamaldehyde in high fat diet (HFD) associated increase in fasting induced hyperphagia and related hormone levels, adipose tissue lipolysis and inflammation, and selected cecal microbial count in mice. Cinnamaldehyde, at 40 uM dose, prevented lipid accumulation and altered gene expression toward lipolytic phenotype in 3T3 L1 preadipocyte cell lines. In vivo, cinnamaldehyde coadministration prevented HFD induced body weight gain, decreased fasting induced hyperphagia, as well as circulating leptin and leptin/ghrelin ratio. In addition to that, cinnamaldehyde altered serum biochemical parameters related to lipolysis, that is, glycerol and free fatty acid levels. At transcriptional level, cinnamaldehyde increased anorectic gene expression in hypothalamus and lipolytic gene expression in visceral white adipose tissue. Furthermore, cinnamaldehyde also decreased serum IL 1b and inflammatory gene expression in visceral white adipose tissue. However, cinnamaldehyde did not modulate the population of selected gut microbial (Lactobacillus, Bifidibaceria, and Roseburia) count in cecal content. In conclusion, cinnamaldehyde increased adipose tissue lipolysis, decreased fasting induced hyperphagia, normalized circulating levels of leptin/ghrelin ratio, and reduced inflammation in HFD fed mice, which augurs well for its antiobesity role.
BioFactors